April 2024 - ELIAS Animal Health

ELIAS Animal Health Expands Manufacturing Capacity Ahead of Product Approval and Pipeline Expansion

OLATHE, Kan., April 30, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, is expanding its manufacturing capacity in a larger facility located in Lenexa, Kansas as it prepares for the commercial product launch of the ELIAS Cancer Immunotherapy (ECI®) later this year. In January 2024, ECI® was determined by the USDA as demonstrating a reasonable expectation of efficacy, a significant milestone in the pathway to product licensure, and a significant milestone in veterinary oncology. ECI® is poised to be the only adoptive cell therapy of its kind approved for the treatment of canine osteosarcoma, a deadly form of bone cancer in dogs. Osteosarcoma is one of the top five cancers in dogs and yet little innovation has been achieved in treating this disease. The historical standard of care for treating canine osteosarcoma has been off-label chemotherapy. With ECI®’s pioneer position as a therapy specifically indicated [...]

By Jessica Wiley|2024-07-17T12:33:12-06:00April 30th, 2024|Categories: News, Press Releases|0 Comments

ELIAS Animal Health Appoints Chief Revenue Officer; Launches Fundraising Round to Support Commercialization and Development of Innovative Canine Cancer Therapies

Experienced executive will lead launch of the first USDA-approved immunotherapy for the treatment of bone cancer in dogs OLATHE, Kan., April 10, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced the appointment of Brian Segebrecht as Chief Revenue Officer in anticipation of the impending product approval of the ELIAS Cancer Immunotherapy (ECI®) in Q4. Segebrecht joins the ELIAS leadership team after recently leading Sentrx Animal Care as CEO to a point of exit in 2023. At ELIAS, he will lead the commercialization of the company’s first-in-class adoptive cell therapy, as well as drive new business partnerships for the expanding product pipeline at ELIAS. “Brian’s track record of transforming commercial strategy and building value for shareholders make him the perfect fit as we move closer to the regulatory approval of ECI® in Q4 of 2024,” said Tammie Wahaus, CEO of ELIAS Animal Health. “His leadership [...]

By Jessica Wiley|2024-07-17T12:35:48-06:00April 10th, 2024|Categories: News, Press Releases|Tags: cancer immunotherapy, elias leadership|0 Comments

PODCAST: ELIAS returns to Dog Cancer Answers to Talk About Alternatives to Chemotherapy

ELIAS Animal Health CEO, Tammie Wahaus, returns to the Dog Cancer Answers podcast to talk about ECI® as an alternative treatment to chemotherapy for canine osteosarcoma. Earlier this year the USDA determined that ECI® has demonstrated a reasonable expectation of efficacy, a major milestone in the product licensure pathway. Listen to the episode below to find out what's next for ECI®, or read the full transcript at Dog Cancer Answers online. Listen to more episodes of the Dog Cancer Answers podcast here.

By Jessica Wiley|2024-05-14T12:42:13-06:00April 1st, 2024|Categories: Blog|Tags: canine osteosarcoma, chemotherapy, ECI|0 Comments